Full text biomedical articles

A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles

Flávia Sousa, Andrea Cruz, Pedro Fonte, Inês Mendes Pinto, Maria Teresa Neves-Petersen, Bruno Sarmento
Sci Rep. 2017; 7: 3736. Published online 2017 Jun 16. doi: 10.1038/s41598-017-03959-4


Article   |   PubReader   |   PDF–1.8M   |   Cite

Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy

Frank Saran, Olivier L. Chinot, Roger Henriksson, Warren Mason, Wolfgang Wick, Timothy Cloughesy, Sunita Dhar, Emanuela Pozzi, Josep Garcia, Ryo Nishikawa
Neuro Oncol. 2016 Jul; 18(7): 991–1001. Published online 2016 Jan 24. doi: 10.1093/neuonc/nov300


Article   |   PubReader   |   PDF–344K   |   Cite

Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer

Cheryl S. W. Li, Kevin Sweeney, Carol Cronenberger
Cancer Chemother Pharmacol. 2020; 85(3): 487–499. Published online 2019 Nov 26. doi: 10.1007/s00280-019-03946-8


Article   |   PubReader   |   PDF–4.5M   |   Cite

Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma

Christophe Lallemand, Rosa Ferrando-Miguel, Michael Auer, Sarah Iglseder, Theresa Czech, Anouk Gaber-Wagener, Franziska Di Pauli, Florian Deisenhammer, Michael G. Tovey
Front Immunol. 2020; 11: 515556. Published online 2020 Oct 15. doi: 10.3389/fimmu.2020.515556


Article   |   PubReader   |   PDF–2.1M   |   Cite

Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer

Carolyn E Haunschild, Krishnansu S Tewari
Future Oncol. 2020 Mar; 16(7): 225–246. Published online 2019 Nov 20. doi: 10.2217/fon-2019-0042


Article   |   PubReader   |   PDF–1.5M   |   Cite

PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study

Niels Reinmuth, Maciej Bryl, Igor Bondarenko, Kostas Syrigos, Vladimir Vladimirov, Manuela Zereu, Angel H. Bair, Fiona Hilton, Katherine Liau, Kazuo Kasahara
BioDrugs. 2019; 33(5): 555–570. Published online 2019 Jul 23. doi: 10.1007/s40259-019-00363-4


Article   |   PubReader   |   PDF–785K   |   Cite

Heparin potentiates Avastin-mediated inhibition of VEGF binding to fibronectin and rescues Avastin activity at acidic pH

Divyabharathy Tsiros, Casey E. Sheehy, Surenna Pecchia, Matthew A. Nugent
J Biol Chem. 2019 Nov 15; 294(46): 17603–17611. Published online 2019 Oct 10. doi: 10.1074/jbc.RA119.009194


Article   |   PubReader   |   PDF–1.3M   |   Cite

Glioblastoma endothelium drives bevacizumab‐induced infiltrative growth via modulation of PLXDC1

Maria Laura Falchetti, Quintino Giorgio D'Alessandris, Simone Pacioni, Mariachiara Buccarelli, Liliana Morgante, Stefano Giannetti, Valentina Lulli, Maurizio Martini, Luigi Maria Larocca, Eliza Vakana, Louis Stancato, Lucia Ricci‐Vitiani, Roberto Pallini
Int J Cancer. 2019 Mar 15; 144(6): 1331–1344. Published online 2018 Dec 16. doi: 10.1002/ijc.31983


Article   |   PubReader   |   PDF–4.4M   |   Cite

Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications

Jiaxin Liu, Xueyan Zhang, Ge Li, Fei Xu, Shuang Li, Lesheng Teng, Youxin Li, Fengying Sun
Int J Nanomedicine. 2019; 14: 8819–8834. Published online 2019 Nov 8. doi: 10.2147/IJN.S217038


Article   |   PubReader   |   PDF–12M   |   Cite

A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin® (EU and US) in healthy male subjects

Chris Wynne, Christian Schwabe, Sonica Sachdeva Batra, Luis Lopez‐Lazaro, Suresh Kankanwadi
Br J Clin Pharmacol. 2018 Oct; 84(10): 2352–2364. Published online 2018 Jul 26. doi: 10.1111/bcp.13691


Article   |   PubReader   |   PDF–444K   |   Cite

Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration

Lorenzo Moja, Ersilia Lucenteforte, Koren H Kwag, Vittorio Bertele, Annalisa Campomori, Usha Chakravarthy, Roberto D’Amico, Kay Dickersin, Laurent Kodjikian, Kristina Lindsley, Yoon Loke, Maureen Maguire, Daniel F Martin, Alessandro Mugelli, Bernd Mühlbauer, Isabel Püntmann, Barnaby Reeves, Chris Rogers, Christine Schmucker, Manju L Subramanian, Gianni Virgili
Cochrane Database Syst Rev. Author manuscript; available in PMC 2015 Sep 15.
Published in final edited form as: Cochrane Database Syst Rev. 2014; 9: CD011230. Published online 2014 Sep 15. doi: 10.1002/14651858.CD011230.pub2


Article   |   PubReader   |   PDF–6.3M   |   Cite

Bevacizumab for glioblastoma: current indications, surgical implications, and future directions

Brandyn A. Castro, Manish K. Aghi
Neurosurg Focus. Author manuscript; available in PMC 2016 Apr 21.
Published in final edited form as: Neurosurg Focus. 2014 Dec; 37(6): E9.


Article   |   PubReader   |   PDF–310K   |   Cite

Use of bevacizumab in recurrent glioblastoma

Ashley Ghiaseddin, Katherine B Peters
CNS Oncol. 2015 May; 4(3): 157–169. Published online 2015 Apr 23. doi: 10.2217/cns.15.8


Article   |   PubReader   |   PDF–1.5M   |   Cite

A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers

Donghoon Shin, Yoon Jung Lee, Jihye Choi, Dahyoung Lee, Minjeong Park, Magdalena Petkova
Cancer Chemother Pharmacol. 2020; 86(4): 567–575. Published online 2020 Sep 19. doi: 10.1007/s00280-020-04144-7


Article   |   PubReader   |   PDF–713K   |   Cite

Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes

Douglas A. MacDonald, Joel Martin, Kathir K. Muthusamy, Jiann-Kae Luo, Erica Pyles, Ashique Rafique, Tammy Huang, Terra Potocky, Yang Liu, Jingtai Cao, Françoise Bono, Nathalie Delesque, Pierre Savi, John Francis, Ali Amirkhosravi, Todd Meyer, Carmelo Romano, Meredith Glinka, George D. Yancopoulos, Neil Stahl, Stanley J. Wiegand, Nicholas Papadopoulos
Angiogenesis. 2016; 19: 389–406. Published online 2016 May 27. doi: 10.1007/s10456-016-9515-8


Article   |   PubReader   |   PDF–7.0M   |   Cite

A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab

Clare T. Butler, Alison L. Reynolds, Miriam Tosetto, Eugene T. Dillon, Patrick J. Guiry, Gerard Cagney, Jacintha O'Sullivan, Breandán N. Kennedy
J Biol Chem. 2017 Mar 3; 292(9): 3552–3567. Published online 2016 Dec 29. doi: 10.1074/jbc.M116.747766


Article   |   PubReader   |   PDF–5.2M   |   Cite

Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy

Jian-Guo Sun, Qin Jiang, Xiao-Pei Zhang, Kun Shan, Bai-Hui Liu, Chen Zhao, Biao Yan
Int J Nanomedicine. 2019; 14: 1489–1501. Published online 2019 Feb 25. doi: 10.2147/IJN.S195504


Article   |   PubReader   |   PDF–2.7M   |   Cite

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

Sharon D Solomon, Kristina Lindsley, Satyanarayana S Vedula, Magdalena G Krzystolik, Barbara S Hawkins, Cochrane Eyes and Vision Group
Cochrane Database Syst Rev. 2019 Mar; 2019(3): CD005139. Published online 2019 Mar 4. doi: 10.1002/14651858.CD005139.pub4


Article   |   PubReader   |   PDF–1.3M   |   Cite

Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario

Prashant Jain, Jay Sheth, Giridhar Anantharaman, Mahesh Gopalakrishnan
Indian J Ophthalmol. 2017 Jul; 65(7): 596–602. doi: 10.4103/ijo.IJO_992_16


Article   |   PubReader   |   PDF–662K   |   Cite

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients

Eirini Panoilia, Emilie Schindler, Epaminontas Samantas, Gerasimos Aravantinos, Haralabos P. Kalofonos, Christos Christodoulou, George P. Patrinos, Lena E. Friberg, Gregory Sivolapenko
Cancer Chemother Pharmacol. 2015; 75(4): 791–803. Published online 2015 Feb 17. doi: 10.1007/s00280-015-2701-3


Article   |   PubReader   |   PDF–713K   |   Cite